Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 12/2016

01-12-2016 | Original Article

Prevalence and antibiotic susceptibility of Ureaplasma urealyticum and Mycoplasma hominis in Xi’an, China

Authors: X.-Y. Zeng, N. Xin, X.-N. Tong, J.-Y. Wang, Z.-W. Liu

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 12/2016

Login to get access

Abstract

This study analyzed the prevalence and antibiotic susceptibility of urogenital Ureaplasma urealyticum and Mycoplasma hominis isolated in Xi’an, China. A total of 2161 individuals from 2011 to 2015 were included, and antibiotic susceptibility tests were performed by using the Mycoplasma IST kit. Of the individuals studied, 1018 (47.11 %) were identified to be positive for urogenital mycoplasmas. The single U. urealyticum, single M. hominis, and dual U. urealyticum and M. hominis infections accounted for 772 (75.83 %), 66 (6.48 %), and 180 (17.68 %), respectively. The total positive rate was higher in females than in males (58.76 % vs. 28.86 %, p < 0.001). The highest total positive rate (48.88 %) was observed in individuals aged 25 years to 30 years. In symptomatic and asymptomatic individuals, the positive rates were both higher in females than in males (67.36 % vs. 31.02 %, p < 0.001 and 42.58 % vs. 7.69 %, p < 0.001, respectively) and individuals aged 25 years to 30 years, and those aged 30 years to 35 years had the highest positive rates (54.35 and 57.14 %, respectively). The U. urealyticum and M. hominis identified from single or dual infections displayed low resistance rates to josamycin, doxycycline, and minocycline (<10 %) in both the symptomatic and asymptomatic groups. These results suggest that females and individuals with symptoms and younger age had higher mycoplasma infection rates and that josamycin, doxycycline, and minocycline may be recommended for the clinical treatment of patients infected with urogenital mycoplasmas, irrespective of the symptoms.
Appendix
Available only for authorised users
Literature
1.
go back to reference Leli C, Mencacci A, Bombaci JC, D’Alò F, Farinelli S, Vitali M, Montagna P, Bietolini C, Meucci M, Perito S, Bistoni F (2012) Prevalence and antimicrobial susceptibility of Ureaplasma urealyticum and Mycoplasma hominis in a population of Italian and immigrant outpatients. Infez Med 20(2):82–87PubMed Leli C, Mencacci A, Bombaci JC, D’Alò F, Farinelli S, Vitali M, Montagna P, Bietolini C, Meucci M, Perito S, Bistoni F (2012) Prevalence and antimicrobial susceptibility of Ureaplasma urealyticum and Mycoplasma hominis in a population of Italian and immigrant outpatients. Infez Med 20(2):82–87PubMed
5.
go back to reference Okeke IN, Laxminarayan R, Bhutta ZA, Duse AG, Jenkins P, O’Brien TF, Pablos-Mendez A, Klugman KP (2005) Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis 5(8):481–493. doi:10.1016/S1473-3099(05)70189-4 CrossRefPubMed Okeke IN, Laxminarayan R, Bhutta ZA, Duse AG, Jenkins P, O’Brien TF, Pablos-Mendez A, Klugman KP (2005) Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis 5(8):481–493. doi:10.​1016/​S1473-3099(05)70189-4 CrossRefPubMed
6.
go back to reference Skiljevic D, Mirkov D, Vukicevic J (2016) Prevalence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum in genital samples collected over 6 years at a Serbian university hospital. Indian J Dermatol Venereol Leprol 82(1):37–41. doi:10.4103/0378-6323.172903 CrossRefPubMed Skiljevic D, Mirkov D, Vukicevic J (2016) Prevalence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum in genital samples collected over 6 years at a Serbian university hospital. Indian J Dermatol Venereol Leprol 82(1):37–41. doi:10.​4103/​0378-6323.​172903 CrossRefPubMed
8.
go back to reference Song T, Ye A, Xie X, Huang J, Ruan Z, Kong Y, Song J, Wang Y, Chen J, Zhang J (2014) Epidemiological investigation and antimicrobial susceptibility analysis of Ureaplasma species and Mycoplasma hominis in outpatients with genital manifestations. J Clin Pathol 67(9):817–20. doi:10.1136/jclinpath-2014-202248 CrossRefPubMed Song T, Ye A, Xie X, Huang J, Ruan Z, Kong Y, Song J, Wang Y, Chen J, Zhang J (2014) Epidemiological investigation and antimicrobial susceptibility analysis of Ureaplasma species and Mycoplasma hominis in outpatients with genital manifestations. J Clin Pathol 67(9):817–20. doi:10.​1136/​jclinpath-2014-202248 CrossRefPubMed
9.
go back to reference Kouegnigan Rerambiah L, Ndong JC, Medzegue S, Elisee-Ndam M, Djoba Siawaya JF (2015) Genital Mycoplasma infections and their resistance phenotypes in an African setting. Eur J Clin Microbiol 34(6):1087–1090. doi:10.1007/s10096-015-2326-9 CrossRef Kouegnigan Rerambiah L, Ndong JC, Medzegue S, Elisee-Ndam M, Djoba Siawaya JF (2015) Genital Mycoplasma infections and their resistance phenotypes in an African setting. Eur J Clin Microbiol 34(6):1087–1090. doi:10.​1007/​s10096-015-2326-9 CrossRef
10.
go back to reference Pónyai K, Mihalik N, Ostorházi E, Farkas B, Párducz L, Marschalkó M, Kárpáti S, Rozgonyi F (2013) Incidence and antibiotic susceptibility of genital Mycoplasmas in sexually active individuals in Hungary. Eur J Clin Microbiol Infect Dis 32(11):1423–1426. doi:10.1007/s10096-013-1892-y CrossRefPubMed Pónyai K, Mihalik N, Ostorházi E, Farkas B, Párducz L, Marschalkó M, Kárpáti S, Rozgonyi F (2013) Incidence and antibiotic susceptibility of genital Mycoplasmas in sexually active individuals in Hungary. Eur J Clin Microbiol Infect Dis 32(11):1423–1426. doi:10.​1007/​s10096-013-1892-y CrossRefPubMed
11.
12.
go back to reference De Francesco MA, Caracciolo S, Bonfanti C, Manca N (2013) Incidence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum isolated in Brescia, Italy, over 7 years. J Infect Chemother 19(4):621–627. doi:10.1007/s10156-012-0527-z CrossRefPubMed De Francesco MA, Caracciolo S, Bonfanti C, Manca N (2013) Incidence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum isolated in Brescia, Italy, over 7 years. J Infect Chemother 19(4):621–627. doi:10.​1007/​s10156-012-0527-z CrossRefPubMed
15.
16.
go back to reference Zhu C, Liu J, Ling Y, Dong C, Wu T, Yu X, Hou Y, Dong L, Cheng X (2012) Prevalence and antimicrobial susceptibility of Ureaplasma urealyticum and Mycoplasma hominis in Chinese women with genital infectious diseases. Indian J Dermatol Venereol Leprol 78(3):406–407. doi:10.4103/0378-6323.95480 CrossRefPubMed Zhu C, Liu J, Ling Y, Dong C, Wu T, Yu X, Hou Y, Dong L, Cheng X (2012) Prevalence and antimicrobial susceptibility of Ureaplasma urealyticum and Mycoplasma hominis in Chinese women with genital infectious diseases. Indian J Dermatol Venereol Leprol 78(3):406–407. doi:10.​4103/​0378-6323.​95480 CrossRefPubMed
17.
go back to reference Okeke IN, Klugman KP, Bhutta ZA, Duse AG, Jenkins P, O’Brien TF, Pablos-Mendez A, Laxminarayan R (2005) Antimicrobial resistance in developing countries. Part II: strategies for containment. Lancet Infect Dis 5(9):568–580. doi:10.1016/S1473-3099(05)70217-6 CrossRefPubMed Okeke IN, Klugman KP, Bhutta ZA, Duse AG, Jenkins P, O’Brien TF, Pablos-Mendez A, Laxminarayan R (2005) Antimicrobial resistance in developing countries. Part II: strategies for containment. Lancet Infect Dis 5(9):568–580. doi:10.​1016/​S1473-3099(05)70217-6 CrossRefPubMed
Metadata
Title
Prevalence and antibiotic susceptibility of Ureaplasma urealyticum and Mycoplasma hominis in Xi’an, China
Authors
X.-Y. Zeng
N. Xin
X.-N. Tong
J.-Y. Wang
Z.-W. Liu
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 12/2016
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-016-2745-2

Other articles of this Issue 12/2016

European Journal of Clinical Microbiology & Infectious Diseases 12/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.